Clinical Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium Infection and Cancer: Biology, Therapeutics, and Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pommier, Y.
Right arrow Articles by Kohn, K. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pommier, Y.
Right arrow Articles by Kohn, K. W.
Clinical Cancer Research Vol. 12, 2657-2661, May 1, 2006
© 2006 American Association for Cancer Research

Molecular Pathways

Chk2 Molecular Interaction Map and Rationale for Chk2 Inhibitors

Yves Pommier, John N. Weinstein, Mirit I. Aladjem and Kurt W. Kohn

Authors' Affiliation: Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland

Requests for reprints: Yves Pommier, NIH, Room 5068, Building 37, Bethesda, MD 20892-4255. E-mail: pommier{at}nih.gov.

To organize the rapidly accumulating information on bioregulatory networks related to the histone {gamma}-H2AX-ATM-Chk2-p53-Mdm2 pathways in concise and unambiguous diagrams, we used the molecular interaction map notation (http://discover.nci.nih.gov/min). Molecular interaction maps are particularly useful for networks that include protein-protein binding and posttranslational modifications (e.g., phosphorylation). Both are important for nearly all of the proteins involved in DNA double-strand break signaling. Visualizing the regulatory circuits underlying cellular signaling may help identify key regulatory reactions and defects that can serve as targets for anticancer drugs.




This article has been cited by other articles:


Home page
 Nucleic Acids ResHome page
M. Tozluoglu, E. Karaca, T. Haliloglu, and R. Nussinov
Cataloging and organizing p73 interactions in cell cycle arrest and apoptosis
Nucleic Acids Res., September 1, 2008; 36(15): 5033 - 5049.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
V. T. Mihaylova, A. M. Green, M. Khurgel, O. J. Semmes, and G. M. Kupfer
Human T-Cell Leukemia Virus I Tax Protein Sensitizes p53-Mutant Cells to DNA Damage
Cancer Res., June 15, 2008; 68(12): 4843 - 4852.
[Abstract] [Full Text] [PDF]

Home page
 Am Soc Clin Oncol Ed BookHome page
Y. Pommier
DNA Repair Modulators as Anticancer Agents
ASCO Educational Book, January 1, 2008; 2008(1): 128 - 133.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
A. G. Jobson, J. H. Cardellina II, D. Scudiero, S. Kondapaka, H. Zhang, H. Kim, R. Shoemaker, and Y. Pommier
Identification of a Bis-guanylhydrazone [4,4'-Diacetyldiphenylurea-bis(guanylhydrazone); NSC 109555] as a Novel Chemotype for Inhibition of Chk2 Kinase
Mol. Pharmacol., October 1, 2007; 72(4): 876 - 884.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
V. A. Rao, C. Conti, J. Guirouilh-Barbat, A. Nakamura, Z.-H. Miao, S. L. Davies, B. Sacca, I. D. Hickson, A. Bensimon, and Y. Pommier
Endogenous {gamma}-H2AX-ATM-Chk2 Checkpoint Activation in Bloom's Syndrome Helicase Deficient Cells Is Related to DNA Replication Arrested Forks
Mol. Cancer Res., July 1, 2007; 5(7): 713 - 724.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
S. Ray, S. Shyam, G. C. Fraizer, and A. Almasan
S-phase checkpoints regulate Apo2 ligand/TRAIL and CPT-11-induced apoptosis of prostate cancer cells
Mol. Cancer Ther., April 1, 2007; 6(4): 1368 - 1378.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
H. Takemura, V. A. Rao, O. Sordet, T. Furuta, Z.-H. Miao, L. Meng, H. Zhang, and Y. Pommier
Defective Mre11-dependent Activation of Chk2 by Ataxia Telangiectasia Mutated in Colorectal Carcinoma Cells in Response to Replication-dependent DNA Double Strand Breaks
J. Biol. Chem., October 13, 2006; 281(41): 30814 - 30823.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2006 by the American Association for Cancer Research.